SILEX SYSTEMS LIMITED — Board/Management Information 2015

Jun 30, 2015

==> picture [119 x 41] intentionally omitted <==

Silex Systems Limited A.C.N. 003 372 067

Level 8, Suite 8.03 56 Clarence Street Sydney NSW 2000 Australia PO Box 364 Sydney NSW 2001 Tel: + 61 2 9704 8888 Fax: +61 2 9279 1051 www.silex.com.au

Appointment of New Non-Executive Director

1[st] July 2015

Silex Systems Limited (“Silex”) (ASX: SLX) (OTCQX: SILXY) is pleased to announce the appointment of Mr Robert Lee as a Non-executive Director, effective today. Mr Lee joins Silex as an independent director.

Silex Chair Dr Lisa McIntyre said today, “As part of our ongoing commitment to Board renewal, we are very pleased that Rob has agreed to join the Silex Board. With his extensive executive experience gained throughout his global career, we look forward to the expertise and contribution that he will bring to our Board. Robert’s experience in strategy development and corporate leadership will continue to strengthen and diversify the skill set of our Board.”

Mr Lee brings to the board extensive financial services and investment banking experience acquired over 25 years working in the sector. He is a former Executive Director of Macquarie Group Limited where he also held senior roles in equity capital markets, corporate finance and private equity. Between 2004 and 2008 he was the Managing Director of Macquarie Direct Investments, the Group’s mid-market private equity business. He has served on the boards of numerous companies in Australia, the US and Asia. Robert is currently Executive Chairman of RENEX Group Pty Ltd and is a Non-executive Director of Westmead IVF.

Mr Lee will stand for election by shareholders at the company’s 2015 Annual General Meeting on 17[th] November 2015.

Meanwhile, Non-executive Director Mr Andrew Stock has indicated his intention to shortly retire from the Silex Board at a date to be confirmed. In addition to chairing the Company’s Audit Committee, Andrew has been instrumental in the Board’s effort to position the subsidiary Solar Systems for a potential transaction. Mr Stock will remain on the Board until the induction of Mr Lee is complete and the execution of our major strategic review draws to a close.

Further Information

Further background information for Mr Robert Lee is provided in the Appendix to this announcement.

1 | P a g e

==> picture [72 x 26] intentionally omitted <==

Appendix

Biography – Mr Robert Lee

Robert Lee is an experienced company director, corporate adviser and former executive director of Macquarie Group Limited. During a 20 year career at Macquarie, he held senior roles within the equity capital markets, corporate finance, private equity and principal investments divisions. Between 2004 and 2008 he was Managing Director of Macquarie Direct Investments (MDI), the Group’s mid-market private equity funds management business. In this role he was responsible for managing MDI’s three private investment funds, with over $300 million of committed capital invested across more than 20 portfolio companies.

He has been an adviser, non-executive director and executive director of numerous companies in Australia, the US and Asia. In addition to strong corporate finance and leadership skills, he has worked across multiple industries and geographies. He has a particular interest in assisting Australian companies seeking to commercialise novel industrial technologies in global markets.

Robert holds a Bachelor of Science (with Distinction) from Cornell University and a MBA from Harvard University.

Directorships

Current

• Executive Chairman of RENEX Group Pty Ltd, a Melbourne based environmental services business seeking to deploy innovative pyrolytic kiln soil remediation technology.

• Non-Executive Director of Westmead IVF Limited, a market leading IVF facility located at Westmead Hospital in Western Sydney and owned by Sydney University.

• • Non-Executive Director of Anglican Deaconess Ministries, a charitable fund associated with the Anglican Church.

Previous

• Non-Executive Director of numerous listed and unlisted companies in Australia and the US.

2 | P a g e

==> picture [72 x 26] intentionally omitted <==

Further information on the Company’s activities can be found on the Silex website: www.silex.com.au or by contacting the persons listed below on +61 2 9704 8888:

• Michael Goldsworthy, CEO / Managing Director; or

• Julie Ducie, CFO / Company Secretary

About Silex Systems Limited

In June 2014, a major strategic review of Silex Systems Limited (ASX: SLX) (OTCQX: SILXY) resulted in a significant restructure of the Company. Under the restructure, the Board determined to refocus efforts on the Company’s primary economic asset, the SILEX laser enrichment technology and to significantly reduce cash burn beyond FY 2015.

This strategic review allows Silex to support uranium enrichment technology licensee, GEHitachi Global Laser Enrichment LLC (‘GLE’) in their efforts to bring the SILEX technology to market. Should this be successfully achieved, Silex could earn attractive royalty revenues, under a technology commercialisation and license agreement, signed originally in 2006.

Under the restructure, it was also announced that the transitions to market for subsidiaries Solar Systems and Translucent would be accelerated. These efforts are now well advanced.

For more detailed information on Silex Systems Limited, please visit www.silex.com.au

Forward Looking Statements and Business Risks:

Silex Systems is a research and development Company whose assets are its proprietary rights in various technologies, including, but not limited to, the SILEX technology, Solar Systems technology, and Translucent technology. Several of the Company’s technologies are in the development stage and have not been commercially deployed, and therefore are high-risk. Accordingly, the statements in this announcement regarding the future of the Company’s technologies and commercial prospects are forward looking and actual results could be materially different from those expressed or implied by such forward looking statements as a result of various risk factors.

Some risk factors that could affect future results and commercial prospects include, but are not limited to: results from the SILEX uranium enrichment commercialisation program; the demand for enriched uranium; the risks associated with the development of Solar Systems technology and related marketing activities; the outcomes of the Company’s interests in the development of various semiconductor, photonics and alternative energy technologies; the time taken to develop various technologies; the development of competing technologies; the potential for third party claims against the Company’s ownership of Intellectual Property associated with its numerous technologies; the potential impact of government regulations or policies; and the outcomes of various commercialisation strategies undertaken by the Company.

3 | P a g e